Bristol-Myers (BMY) Acquires Medarex (MEDX) For $16/Share
More News related to BMY
- EPS growth in Q2 2010
- Global Health Care Leader Selects Model N Contract Authoring Solution
- Visionary Keynote Speakers Announced for 2010 European Wine Bloggers Conference
- Bristol-Myers (BMY) Q2 Profits Drop, But Match Street Views
- Bristol-Myers Squibb National Survey Finds a Disparity Between Health Care Providers and HIV Positive Patients Perspectives on the Emotional Barriers to Seeking HIV Care and Treatment
More News related to MEDX
- NRG Energy (NRG) Hires Christian S. Schade as Exec. V.P. and CFO
- Bristol-Myers Squibb (BMY) Completes Acquisition of Medarex
- Bristol-Myers Squibb (BMY) Completes Tender Offer for Medarex (MEDX)
- Notable Mergers and Acquisitions of the Day 8/21: MNOV/AVGN, BMY/MEDX, ORCL/JAVA
- Bristol-Myers (BMY) Extends Tender Offer for Medarex (MEDX) to August 26
More News related to Hot List
- Google (GOOG) Says Mainland China Web Service Fully Blocked -CNBC
- S&P Announces Change to US Index: SHOO for VTIV
- Eastman Chemical (EMN) Reports Q2 Adj-EPS of $2.05; Guides Q3, FY10
- Sierra Wireless (SWIR) Tops Q2 EPS by 6c; Guides Above the Street
- Sunoco (SUN) Tops Q2 EPS by 54c
Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) announced today that the companies have signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
MEDX closed at $8.40/share yesterday.
The transaction, with an aggregate purchase price of approximately $2.4 billion, has been unanimously approved by the boards of directors of both companies. Medarex’s projected $300 million in net cash and marketable securities at closing would be an asset acquired by Bristol-Myers Squibb resulting in an implied purchase price of approximately $2.1 billion.
Bristol-Myers Squibb gains the following as a result of the acquisition:
- Medarex’s UltiMAb Human Antibody Development System®, which produces high affinity, fully human antibodies for use in a broad range of therapeutic areas, including immunology and oncology. This validated technology platform has produced compounds which are now currently marketed therapies (SIMPONI™, STELARA™ and ILARIS®).
- Medarex’s next-generation Antibody-Drug Conjugate (ADC) technology, which is a novel and proprietary platform that could open new fields in oncology drug development.
- Rights to seven antibodies in clinical trials under Medarex’s sole sponsorship and three other antibodies being co-developed with other partners. Rights to pre-clinical assets in various stages of development by Medarex -- in particular, monoclonal antibodies focused in oncology and immunology.
- Full ownership and rights to ipilimumab, which, if approved, could be an important contributor to Bristol-Myers Squibb’s future growth. The companies have collaborated on the development of ipilimumab, a novel immunotherapy currently in Phase III development for the treatment of metastatic melanoma. The companies also have an ongoing Phase II study in lung cancer as well as Phase III studies in adjuvant melanoma and hormone-refractory prostate cancer.
- Royalties based on percentage of sales for SIMPONI™, STELARA™ and ILARIS®.
Related Categories
Hot ListMergers and Acquisitions
Stocks Mentioned
-0.04
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
